BJDXHIGH SIGNALRISK10-K

BJDX faces imminent delisting risk from a newly proposed $5 million Nasdaq market value requirement that they cannot currently satisfy.

The company has disclosed a critical new delisting threat beyond the typical $1.00 share price requirement, indicating severe market capitalization distress. Despite improved cash burn and operating performance, the fundamental viability of the company's public listing status is now in immediate jeopardy, which would severely limit access to capital markets and institutional investors.

Comparing 2026-03-06 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows mixed signals with operating cash flow burn improving 22.6% to -$6.1M and net losses narrowing 11.3% to -$6.8M, driven by significant reductions in SG&A (-37.2%) and R&D expenses (-12.2%). However, current liabilities surged 38.1% to $1.1M despite cash increasing 20.1% to $5.2M, suggesting potential working capital pressures. While the company has reduced its burn rate and maintained adequate cash reserves, the operational improvements are overshadowed by the existential threat of imminent delisting due to insufficient market capitalization.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-43.4%
$307K→$174K

Capex reduced 43.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+38.1%
$810K→$1.1M

Current liabilities surged 38.1% — significant near-term obligations; verify ability to meet short-term debt.

SG&A Expense
P&L
-37.2%
$451K→$283K

SG&A reduced 37.2% — improved cost efficiency or headcount reduction improving operating margins.

Total Liabilities
Balance Sheet
+23.3%
$928K→$1.1M

Liabilities increased 23.3% — monitor debt-to-equity ratio and interest coverage.

Operating Cash Flow
Cash Flow
+22.6%
-$7.8M→-$6.1M

Operating cash flow grew 22.6% — strong conversion of earnings to cash, healthy business fundamentals.

Cash & Equivalents
Balance Sheet
+20.1%
$4.3M→$5.2M

Cash grew 20.1% — improving liquidity position supports investment and shareholder returns.

R&D Expense
P&L
-12.2%
$3.5M→$3.0M

R&D spending cut 12.2% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
+11.5%
$4.9M→$5.5M

Current assets grew 11.5% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
+11.3%
-$7.7M→-$6.8M

Net income grew 11.3% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-06
PRIOR — 2025-03-31
ADDED
As of March 2, 2026, there were 972,215 shares of the registrant s common stock, par value $0.0001 per share, outstanding.
SPECIAL NOTE REGARDING COMPANY REFERENCES In this Form 10-K, and unless the context otherwise requires, Bluejay Diagnostics, Inc.
Our common stock is currently listed for quotation on the Nasdaq Capital Market, but we may be unable to meet requirements for continued listing in the future, particularly if our common stock trades below $1.00 per share in the future.
In addition, Nasdaq has recently proposed a new $5 million market value of listed securities requirement that we would not currently satisfy and therefore could cause our common stock be delisted by Nasdaq on an imminent basis, if approved by the SEC.
Our license arrangements with Toray, which relate to the license of the core technology used in our Symphony Cartridges for Sanyoseiko Co., Ltd.
( Sanyoseiko ) to manufacture cartridges for Bluejay, are subject to risks that may threaten our viability or otherwise have a material adverse effect on us and our business, assets and its prospects.
Certain processes related to manufacturing have been the cause of prior performance and reproducibility issues with our cartridge product and we do not expect to be able to test our clinical trial samples until such manufacturing issues have been confirmed to be resolved.
Our analytical validation, required for FDA clearance, may take longer than expected.
( Bluejay ) is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis.
We are working on developing rapid, near-patient tests using whole blood on our Symphony technology platform ( Symphony ), which consists of an analyzer and single-use protein detection cartridges.
REMOVED
As of March 21, 2025, there were 554,012 shares of the registrant s common stock, par value $0.0001 per share, outstanding.
SPECIAL NOTE REGARDING COMPANY REFERENCES In this Form 10-K, and unless the context otherwise requires, the Company, we, us and our refer to Bluejay Diagnostics, Inc.
and its wholly-owned subsidiary Bluejay Spinco, LLC, taken as a whole.
We will require material additional funding to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, or at all, and our lack of cash resources has slowed the timeline of our clinical trial work and could cause us to run out of cash resources in the near-term.
Our common stock is currently listed for quotation on the Nasdaq Capital Market, but we may be unable to meet requirements for continued listing in the future.
We may be obligated to current and/or prior financial advisors under engagement letters that we enter into from time to time.
We do not currently have sufficient supply of, or know-how from Toray to produce the capture antibody for our cartridges that we currently depend on.
We might not be able to discover the underlying cause of an ongoing performance reproducibility issue with our product, and if the issues are ultimately determined to be inherent in the design process of the platform, we might have to undertake a significant adjustment to our process and materials.
Our ability to solve ongoing issues with critical raw material supply, stability, and reliability of the Symphony Cartridge product may adversely impact our ability to complete clinical trial work and commercialize Symphony.
Our Symphony platform may be sold as a research use only product.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →